TUESDAY, July 19, 2016 (HealthDay News) \u2014 New cases of advanced prostate cancer in the United States have skyrocketed 72 percent in the past decade, a troubling new study shows.<\/p>\n
The biggest increase was among men aged 55 to 69, with a 92 percent jump seen over 10 years. This rise is worrisome because these men are the ones who may benefit most from screening and early treatment, the researchers said.<\/p>\n
\u201cThe increase could be because the disease is becoming more aggressive, or it could be because there is less screening being done, but we don\u2019t know why,\u201d said lead researcher Dr. Edward Schaeffer. He is chair of urology at Northwestern University\u2019s Feinberg School of Medicine in Chicago.<\/p>\n
It\u2019s possible that prostate cancer may be getting more aggressive, Schaeffer said, but statistics also show that fewer men are being screened. That\u2019s the probable consequence of a 2012 recommendation by the U.S. Preventive Services Task Force that said men should not be screened for prostate-specific antigen (PSA). PSA, a protein produced by cells of the prostate gland, is often elevated in men with prostate cancer.<\/p>\n
\u201cMy major issue with the U.S. Preventive Services Task Force recommendation was it completely excluded the patient from the decision-making process,\u201d Schaeffer said. \u201cPSA screening saves lives, period.\u201d<\/p>\n
The men in the study who were diagnosed in 2013 versus 2004 had higher PSAs \u2014 twice as high \u2014 which implies that these men were not well screened, Schaeffer said.<\/p>\n
However, since advanced cancer cases began increasing before the change in the screening recommendation, researchers can\u2019t definitively link the increase in cases to reduced screening alone, Schaeffer said. And this study was not designed to prove that either factor caused an increase in advanced prostate cancer cases.<\/p>\n
Men should talk with their doctor about being screened for prostate cancer, Schaeffer said. For men with an average risk, screening should start at 50. For men at increased risk, screening should start at 40. Screening can stop when a man has less than 10 years of life expectancy, he said.<\/p>\n
\u201cIf you screen, you can reduce the number of men who present with metastatic cancer, that\u2019s what I believe,\u201d Schaeffer said.<\/p>\n
For the study, Schaeffer and his colleagues collected data on nearly 800,000 men listed in the National Cancer Data Base who had been diagnosed with prostate cancer between 2004 and 2013.<\/p>\n
Among these men, 3 percent had advanced prostate cancer, called metastatic cancer, in which cancer cells had spread beyond the prostate to other organs of the body.<\/p>\n
The number of these cases was 72 percent higher in 2013 than it was in 2004, the researchers found.<\/p>\n
The report was published July 19 in the journal Prostate Cancer and Prostatic Diseases<\/i>.<\/p>\n
Dr. Anthony D\u2019Amico is chief of radiation oncology at Brigham and Women\u2019s Hospital in Boston. He said the study showed that men with high-risk prostate cancer weren\u2019t routinely screened with a bone scan and a C-scan of the pelvis, which would detect metastatic cancer. This may account for the rise in metastatic cancer among high-risk patients before the 2012 screening recommendation, he added.<\/p>\n
\u201cIf you have high-risk prostate cancer, make sure your doctor orders a bone scan and a C-scan of the pelvis to rule out the possibility of metastatic disease, which is almost always lethal,\u201d he said.<\/p>\n
D\u2019Amico also disagrees with the task force\u2019s recommendation.<\/p>\n
\u201cMen at risk for prostate cancer, including black men, should be screened for PSA starting at 40,\u201d he said. \u201cMen at average risk should be screened starting at 50 with a base screening in their 30s.\u201d<\/p>\n
More information<\/b><\/p>\n
Visit the American Cancer Society<\/a> SOURCES: Edward Schaeffer, M.D., Ph.D., chair, urology, Northwestern University Feinberg School of Medicine, Chicago; Anthony D\u2019Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women\u2019s Hospital, Boston; July 19, 2016, Prostate Cancer and Prostatic Diseases<\/i>![\"External](\"https:\/\/healthfinder.gov\/images\/exit_disclaimer.png\")
<\/a> \u00a0\u00a0 for more on prostate cancer.<\/p>\n
\nCopyright \u00a9 2016 HealthDay<\/a> <\/a>. \u00a0 All rights reserved.<\/p>\n